Iterum Therapeutics plc - Ordinary Share (ITRM): Price and Financial Metrics


Iterum Therapeutics plc - Ordinary Share (ITRM): $0.21

0.01 (+6.59%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ITRM Stock Price Chart Interactive Chart >

Price chart for ITRM

ITRM Price/Volume Stats

Current price $0.21 52-week high $1.63
Prev. close $0.20 52-week low $0.18
Day low $0.20 Volume 1,139,086
Day high $0.23 Avg. volume 1,357,304
50-day MA $0.23 Dividend yield N/A
200-day MA $0.39 Market Cap 39.13M

Iterum Therapeutics plc - Ordinary Share (ITRM) Company Bio


Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is based in Dublin, Ireland.


ITRM Latest News Stream


Event/Time News Detail
Loading, please wait...

ITRM Latest Social Stream


Loading social stream, please wait...

View Full ITRM Social Stream

Latest ITRM News From Around the Web

Below are the latest news stories about Iterum Therapeutics plc that investors may wish to consider to help them evaluate ITRM as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We've got another busy week of trading ahead of us so let's start it off with the biggest pre-market stock movers for Monday!

William White on InvestorPlace | February 28, 2022

Iterum Therapeutics plc: How Does ITRM Perform?

The trading price of Iterum Therapeutics plc (NASDAQ:ITRM) closed lower on Monday, December 13, closing at $0.47, -1.88% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

Stocks Register | December 14, 2021

Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, Ireland and CHICAGO, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has granted a non-statutory share option to purchase an aggregate of 1,800,000 ordinary shares of Iterum Therapeutics and 500,000 restricted share units to Sailija Puttagunta, M.D., Iterum Therapeutics newly appointed Chief Medical Officer. This grant was awarded pursuant to the Nasdaq inducement grant exception as a component of new hire employment compensation.

Intrado Digital Media | December 14, 2021

Is Iterum Therapeutics (NASDAQ:ITRM) Weighed On By Its Debt Load?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Yahoo | December 14, 2021

Iterum Therapeutics Appoints Sailaja Puttagunta, MD as Chief Medical Officer

DUBLIN, Ireland and CHICAGO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the appointment of Sailaja Puttagunta, M.D., to the newly created position of Chief Medical Officer, where she will oversee global clinical developme

Yahoo | December 13, 2021

Read More 'ITRM' Stories Here

ITRM Price Returns

1-mo -9.09%
3-mo -41.34%
6-mo -46.40%
1-year -90.83%
3-year -96.78%
5-year N/A
YTD -46.40%
2021 -60.38%
2020 -78.02%
2019 -10.18%
2018 N/A
2017 N/A

Continue Researching ITRM

Want to see what other sources are saying about Iterum Therapeutics plc's financials and stock price? Try the links below:

Iterum Therapeutics plc (ITRM) Stock Price | Nasdaq
Iterum Therapeutics plc (ITRM) Stock Quote, History and News - Yahoo Finance
Iterum Therapeutics plc (ITRM) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4881 seconds.